AstraZeneca CEO Pascal Soriot raised questions Tuesday about the company’s future in vaccines while hinting at potential M&A activity on the near horizon.
In an interview with Reuters, Soriot discussed the company's plans, which he said include building on its portfolio of antibody therapies. AstraZeneca is also considering bolt-on acquisitions in oncology and cardiovascular areas, Soriot said.
Getting out of the COVID-19 Vaccine Business?
Overall, in the COVID-19 space, the company has shifted its resources to antibody therapies.
Image: Pascal Claude Roland Soriot - 23 May 1959 (age 63) France - Wikipedia